Mechanism of Action
SGLT2, expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Canagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, canagliflozin reduces reabsorption of filtered glucose and lowers the renal threshold for…
Indications (2)
Clinical Trials (5)
A Study to Assess Safety of Canagliflozin and Metformin Hydrochloride Combination Given as a Supplement to Diet and Exercise to Improve Blood Sugar Level in Indian Adult Participants With Diabetes
A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Impact of a Short-term Treatment With Canagliflozin (Canacardia-HF)
A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
Loss of Exclusivity
Patent Records (5)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 7943788 | Jul 14, 2027 | SubstanceProduct | — |
| 8513202 | Dec 3, 2027 | SubstanceProduct | U-2441 |
| 7943788*PED | Jan 14, 2028 | — | |
| 8513202*PED | Jun 3, 2028 | — | |
| 7943582 | Feb 26, 2029 | SubstanceProduct | U-493 |